摘要
背景:胶质母细胞瘤一直被认为是脑肿瘤死亡的首要原因,是最具侵袭性和致死性的原因之一。可选的治疗方案如手术、放疗、化疗和靶向治疗,都是不能有效改善预后,所以应坚持替代疗法。由于其协同作用,多靶向的方法和最小的副作用,植物性药物是有效的方法。 方法:通过各种体外和硅片的生物分析工具,评价匙叶甘松根茎提取物(NJRE)对U87 MG细胞株的抗肿瘤的潜力。 结果:NJRE对U87 MG细胞株有较强的抗增殖作用,它的IC50 在24h、48h和72 h之后分别为33.73±3.5、30.59±3.4和28.39±2.9μg/mL,NJRE在 30μg/mL的水平诱导了DNA片段,说明细胞凋亡,早期细胞凋亡在20μg/mL水平开始,然而更高的剂量表明由双重荧光染色所显示了晚期凋亡。NJRE在60μg/mL和80μg/mL水平引起G0/G1阻滞,在20μg/mL和40μg/mL水平显示细胞过高的成核和有丝分裂障碍。免疫印迹法通过内在途径证实了细胞死亡的凋亡模式。NJRE对正常细胞无害。NJRE的标记化合物在硅片上对接:山芹醇,甘松醇,匙叶甘松,宽叶甘松酸和甘松新酮显示他们与内皮细胞生长因子受体2(VEGFR2)、细胞周期蛋白依赖性激酶2(CDK2)、B细胞淋巴瘤2(BCL-2)和表皮生长因子受体(EGFR)的协同和多靶点作用。 结论:本研究可以看到NJRE对U87 MG细胞有强大的明确剂量和时间依赖性的抗肿瘤的潜力。该提取物可用于治疗胶质母细胞瘤安全和多靶向治疗的开发,这之前已被报道过。
关键词: 胶质母细胞瘤、匙叶甘松,抗增殖效应,替代医学研究,分子对接,药物动力学。
图形摘要
Current Cancer Drug Targets
Title:Strong Anti-tumorous Potential of Nardostachys jatamansi Rhizome Extract on Glioblastoma and In Silico Analysis of its Molecular Drug Targets
Volume: 17 Issue: 1
Author(s): Himanshi Kapoor, Nalini Yadav, Madhu Chopra, Sushil Chandra Mahapatra, Veena Agrawal
Affiliation:
关键词: 胶质母细胞瘤、匙叶甘松,抗增殖效应,替代医学研究,分子对接,药物动力学。
摘要: Background: Glioblastoma has been reckoned as the prime cause of death due to brain tumours, being the most invasive and lethal. Available treatment options, i.e. surgery, radiotherapy, chemotherapy and targeted therapies are not effective in improving prognosis, so an alternate therapy is insistent. Plant based drugs are efficient due to their synergistic action, multi-targeted approach and least side effects.
Methods: The anti-tumorous potential of Nardostachys jatamansi rhizome extract (NJRE) on U87 MG cell line was evaluated through various in vitro and in silico bio-analytical tools. Results: NJRE had a strong anti-proliferative effect on U87 MG cells, Its IC50 was 33.73±3.5, 30.59±3.4 and 28.39±2.9 μg/mL, respectively after 24, 48 and 72 h. NJRE at 30 μg/mL induced DNA fragmentation, indicating apoptosis, early apoptosis began in the cells at 20 μg/mL, whereas higher doses exhibited late apoptosis as revealed by dual fluorescence staining. NJRE at 60 and 80 μg /mL caused a G0/G1 arrest and at 20 and 40 μg/mL showed excessive nucleation and mitotic catastrophe in the cells. Immuno-blotting validated the apoptotic mode of cell death through intrinsic pathway. NJRE was harmless to normal cells. In silico docking of NJRE marker compounds: oroselol, jatamansinol, nardostachysin, jatamansinone and nardosinone have revealed their synergistic and multi-targeted interactions with Vestigial endothelial growth factor receptor 2 (VEGFR2), Cyclin dependent kinase 2 (CDK2), B-cell lymphoma 2 (BCL2) and Epidermal growth factor receptor (EGFR). Conclusion: A strong dose specific and time dependent anti-tumorous potential of NJRE on U87 MG cells was seen. The extract can be used for the development of safe and multi-targeted therapy to manage glioblastoma, which has not been reported earlier.Export Options
About this article
Cite this article as:
Himanshi Kapoor, Nalini Yadav, Madhu Chopra, Sushil Chandra Mahapatra, Veena Agrawal , Strong Anti-tumorous Potential of Nardostachys jatamansi Rhizome Extract on Glioblastoma and In Silico Analysis of its Molecular Drug Targets, Current Cancer Drug Targets 2017; 17 (1) . https://dx.doi.org/10.2174/1570163813666161019143740
DOI https://dx.doi.org/10.2174/1570163813666161019143740 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting the Multifaceted HuR Protein, Benefits and Caveats
Current Drug Targets Restoring TRAIL Induced Apoptosis Using Naturopathy. Hercules Joins Hand with Nature to Triumph Over Lernaean Hydra
Current Genomics Identification of Biomarkers and Functional Modules from Genomic Data in Stage-wise Breast Cancer
Current Bioinformatics Fibroblast Growth Factor Receptor Signaling in Cancer Biology and Treatment
Current Signal Transduction Therapy Emerging Role of Circular RNAs in Kidney Diseases in Nephrology
Current Drug Targets Protein Targeting Constructs in Alpha Therapy
Current Radiopharmaceuticals Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer
Medicinal Chemistry Fibroblast Growth Factor-2 Antagonist and Antiangiogenic Activity of Long-Pentraxin 3-Derived Synthetic Peptides
Current Pharmaceutical Design Evaluation of Natural and Synthetic Compounds from East Asiatic Folk Medicinal Plants on the Mediation of Cancer
Anti-Cancer Agents in Medicinal Chemistry Porphyrin-based Sensitizers in the Detection and Treatment of Cancer: Recent Progress
Current Medicinal Chemistry - Anti-Cancer Agents PI3K Inhibitors for Cancer Therapy: What has been Achieved So Far?
Current Medicinal Chemistry Interactions Between Cholinergic and Fibroblast Growth Factor Receptors in Brain Trophism and Plasticity
Current Protein & Peptide Science Lipid-based siRNA Delivery Systems: Challenges, Promises and Solutions Along the Long Journey
Current Pharmaceutical Biotechnology Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Ketogenic Diet and Other Dietary Intervention Strategies in the Treatment of Cancer
Current Medicinal Chemistry Nose-to-Brain Drug Delivery by Nanoparticles in the Treatment of Neurological Disorders
Current Medicinal Chemistry Brain Tumor Detection and Classification by Hybrid CNN-DWA Model Using MR Images
Current Medical Imaging Anti-Angiogenic Approaches to Malignant Gliomas
Current Cancer Drug Targets Elaborating the Role of Natural Products on the Regulation of Autophagy and their Potentials in Breast Cancer Therapy
Current Cancer Drug Targets Salen Mn Complexes Mitigate Radiation Injury in Normal Tissues
Anti-Cancer Agents in Medicinal Chemistry